Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782798 | 0.92 | CYP11B2 (0.43) | PDE10ACYP11B2TSPO | |
| SCHEMBL782548 | 0.88 | CYP11B2 (0.48) | CYP11B2SMN1; SMN2 | |
| SCHEMBL783403 | 0.81 | PTPN5 (0.44) | CYP11B2SMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL14987939 | 0.79 | PDE10A (0.45) | PDE10ATSPOPIK3CD | |
| SCHEMBL805366 | 0.77 | CYP11B2 (0.49) | CYP11B2TSPOSMN1; SMN2 | |
| SCHEMBL805385 | 0.74 | GPR55 (0.46) | CYP11B2SMN1; SMN2 | |
| SCHEMBL782733 | 0.72 | BRPF1 (0.42) | CYP11B2ALDH1A1 | |
| SCHEMBL17969402 | 0.72 | SMN1; SMN2 (0.41) | CYP11B2ALDH1A1SMN1; SMN2ROCK2ROCK1 | |
| SCHEMBL21992183 | 0.72 | MIF (0.52) | ALDH1A1 | |
| SCHEMBL783483 | 0.71 | KCNJ1 (0.53) | CYP11B2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430018-B1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | PDE10A 298/4885CYP11B2 1/4885TSPO 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.